|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
OCTOBER 9, 2006
Calm Those Fears About NeuroMetrix  After NeuroMetrix (NURO
) (NURO) received inquiries about its marketing tactics, rumors of possible federal indictments pummeled the stock. The company, which disclosed the subpoenas voluntarily, doesn't expect further action. The Waltham (Mass.) startup sells devices to diagnose carpal tunnel syndrome and ills associated with back pain or diabetes. More than 4,000 of the units are in use at general practitioners' offices. The stock, priced at 8 in its July, 2004, initial public offering, surged to 40 in May but has fallen to 21.44, as the shorts piled in (43% of the shares have been shorted). "The [alleged] fraud is not substantiated; this stock is manipulated by the shorts," says Ryan Rauch of investment firm Jefferies (JEF
). In a Sept. 19 report, William Quirk of RBC Capital Markets (RY
) added: "Concerns are largely based on false information." Quirk says the stock is worth 50. There's fear in the market about the stock, says David Turkaly of Susquehanna Financial Group. Of course, he adds, "the [NeuroMetrix] technology is pretty disruptive, and the neurology community is unhappy because it sidesteps the specialist." NeuroMetrix was profitable five quarters after its IPO. For this year, Turkaly forecasts a 63% increase in revenues, to $55.8 million, and profits of $4 million (or $7 million, before stock option expenses).
Gene Marcial is on vacation. Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version